Article
Oncology
Gerard M. Walls, John O'Connor, Mark Harbinson, Eamon P. McCarron, Frances Duane, Conor McCann, Peter McKavanagh, David I. Johnston, Jayaraj Erekkath, Valentina Giacometti, Anna T. Gavin, Jonathan McAleese, Alan R. Hounsell, Aidan J. Cole, Karl T. Butterworth, Conor K. McGarry, Gerard G. Hanna, Suneil Jain
Summary: Radiation cardiotoxicity is a major issue for NSCLC patients undergoing radiotherapy. This study explores the impact of statin therapy on overall survival and cardiac events post-radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Christine Son, Melissa Y. Y. Moey, Paul R. Walker, Abdul R. Naqash, Matthew Sean Peach, Andrew W. Ju
Summary: In this retrospective study, data was collected on Stage III-IV lung cancer patients who received immune checkpoint inhibitors (ICIs) between 2015 and 2018. The risk of cardiotoxicity was assessed in patients who received thoracic radiotherapy compared to those who did not, and no significant difference was found in the occurrence of cardiotoxicities between the two groups.
FRONTIERS IN ONCOLOGY
(2023)
Review
Health Care Sciences & Services
Marika Musielak, Wiktoria M. Suchorska, Magdalena Fundowicz, Piotr Milecki, Julian Malicki
Summary: Proton therapy offers a more favorable dose distribution for breast cancer patients, potentially reducing toxicity. However, challenges and prospects for preventing cardiotoxicity remain unclear and require further research.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Biology
Camila Salata, Carlos E. deAlmeida, Samara C. Ferreira-Machado, Regina C. Barroso, Liebert P. Nogueira, Andrea Mantuano, Arissa Pickler, Carla L. Mota, Cherley B. V. de Andrade
Summary: Advancements in breast cancer treatment have significantly improved survival but can lead to potential side effects, especially cardiac toxicity. Side effects may also affect other organs besides the heart.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2021)
Review
Oncology
Zhenkun Fu, Zhoujun Lin, Mao Yang, Chenggang Li
Summary: Breast cancer is a common type of cancer, with surgery being the preferred treatment method. Various adjuvant therapies such as radiotherapy, chemotherapy, endocrine therapy, and targeted drug therapy can also be used.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Eva Kimpe, Amber Werbrouck, Mark De Ridder, Koen Putman
Summary: Radiation-induced cardiotoxicity can cause additional costs and disutility in breast cancer survivors, but these effects are relatively minor. The past investments in achieving current mean heart dose (MHD) seem justified considering the reduction in costs and disutility resulting from radiation-induced cardiovascular events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
N. Fourati, S. Charfeddine, I. Chaffai, F. Dhouib, L. Farhat, M. Boukhris, L. Abid, S. Kammoun, W. Mnejja, J. Daoud
Summary: This prospective study revealed that breast cancer radiotherapy can lead to cardiotoxicity, and using echocardiographic parameters can detect LV dysfunction. In radiotherapy planning, factors such as radiation dose, age, and obesity should be considered.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Review
Health Care Sciences & Services
Vasiliki Nikovia, Evangelos Chinis, Areti Gkantaifi, Maria Marketou, Michalis Mazonakis, Nikolaos Charalampakis, Dimitrios Mavroudis, Kornilia Vasiliki Orfanidou, Antonios Varveris, Chrysostomos Antoniadis, Maria Tolia
Summary: Breast cancer is the most common malignancy in females. Radiotherapy plays an important role in its treatment, but traditional methods can cause cardiotoxicity and cardiovascular diseases. Recent radiotherapeutic techniques have shown potential in reducing post-radiotherapy cardiovascular diseases. This review discusses the role of current cardioprotective strategies in preventing cardiotoxic effects in breast cancer radiotherapy.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Kristin Hsieh, Daniel R. Dickstein, Juliana Runnels, Eric J. Lehrer, Kenneth Rosenzweig, Fred R. Hirsch, Robert M. Samstein
Summary: The emergence of immune checkpoint inhibitors (ICIs) has highlighted the important role of the immune system in cancer treatment. ICIs are being investigated and incorporated into the treatment paradigm for lung cancers at different stages and histology. Currently, definitive concurrent chemoradiotherapy followed by consolidative durvalumab is the recommended treatment for lung cancers including radiotherapy with ICI, but there are other recommendations for ICI with chemotherapy and/or surgery.
Article
Radiology, Nuclear Medicine & Medical Imaging
Alireza Omidi, Elisabeth Weiss, John S. S. Wilson, Mihaela Rosu-Bubulac
Summary: The study aims to establish a workflow for evaluating the dose variation of radiotherapy induced by respiratory and cardiac motion on the left ventricle and left ventricular myocardium. Lung cancer patients underwent 4D-CT, T1-VIBE, and cine MRI scans to design treatment plans and estimate dose variations. The results showed that the dose on the left ventricle was highest during respiration and cardiac motion.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2023)
Review
Immunology
Yao Xiao, Hongqing Zhuang
Summary: The combination of SRT and immunotherapy has shown good clinical efficacy in the treatment of lung cancer. SRT activates the immune system, promotes antigen-antibody response, and induces tumor cell apoptosis. However, dose fractionation and time have an impact on SRT combined immunotherapy, and many issues still require further research.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Alesha A. Thai, Benjamin J. Solomon, Lecia Sequist, Justin F. Gainor, Rebecca S. Heist
Summary: The seminar highlights significant advancements in screening, diagnosis, and treatment of lung cancer in the past two decades, with a specific focus on targeted therapies and immune checkpoint inhibitors. These progressions have transformed outcomes for many patients.
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Chemistry, Multidisciplinary
Xiuli Zheng, Xiaohai Song, Guonian Zhu, Dayi Pan, Haonan Li, Jiankun Hu, Kai Xiao, Qiyong Gong, Zhongwei Gu, Kui Luo, Weimin Li
Summary: Lung cancer, the second most prevalent cancer and the leading cause of cancer-related death, is often accompanied by drug resistance. Nanomedicine, with its multifunctional and tunable physiochemical properties, holds great promise in overcoming drug resistance in lung cancer treatment.
ADVANCED MATERIALS
(2023)
Article
Oncology
Ditte Sloth Moller, Christina Maria Lutz, Azza Ahmed Khalil, Markus Alber, Marianne Ingerslev Holt, Maria Kandi, Hjordis Hjalting Schmidt, Marie Tvilum, Ane Appelt, Marianne Marquard Knap, Lone Hoffmann
Summary: This study investigated the clinical benefits of tumor match and adaptive radiotherapy for non-small cell lung cancer patients. The results showed that tumor match and adaptive radiotherapy significantly reduced the incidence of radiation pneumonitis and improved progression-free and overall survival.
RADIOTHERAPY AND ONCOLOGY
(2022)
Editorial Material
Oncology
A. McWilliam, P. Scarfe
Article
Oncology
Gerard M. Walls, Mihaela Ghita, Rachel Queen, Kevin S. Edgar, Eleanor K. Gill, Refik Kuburas, David J. Grieve, Chris J. Watson, Alan McWilliam, Marcel Van Herk, Kaye J. Williams, Aidan J. Cole, Suneil Jain, Karl T. Butterworth
Summary: This study characterized late changes in gene expression using spatial transcriptomics in a mouse model of base regional radiosensitivity. The results showed that irradiation to the heart base led to reduced ejection fraction and significant gene expression changes in the irradiated regions. Differences in the transcriptional effects of radiation on different cardiac base structures were observed. Understanding the regional radiation response in the heart can guide the development of targeted interventions and dose constraints.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Matthew Craddock, Ursula Nestle, Jochem Koenig, Tanja Schimek-Jasch, Stephanie Kremp, Stefan Lenz, Kathryn Banfill, Angela Davey, Gareth Price, Ahmed Salem, Corinne Faivre-Finn, Marcel van Herk, Alan McWilliam
Summary: This study analyzes the overall survival of patients with inoperable stage II or III NSCLC treated with radiotherapy, and for the first time includes left ventricular ejection fraction as a metric of cardiac function. The results indicate that there is a region within the base of the heart that is significantly associated with worse overall survival, and an interaction between baseline cardiac health and heart base dose was identified.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Respiratory System
Torsten Gerriet Blum, Rebecca L. Morgan, Valerie Durieux, Joanna Chorostowska-Wynimko, David R. Baldwin, Jeanette Boyd, Corinne Faivre-Finn, Francoise Galateau-Salle, Fernando Gamarra, Bogdan Grigoriu, Georgia Hardavella, Michael Hauptmann, Erik Jakobsen, Dragana Jovanovic, Paul Knaut, Gilbert Massard, John McPhelim, Anne-Pascale Meert, Robert Milroy, Riccardo Muhr, Luciano Mutti, Marianne Paesmans, Pippa Powell, Paul Martin Putora, Janette Rawlinson, Anna L. Rich, David Rigau, Dirk de Ruysscher, Jean-Paul Sculier, Arnaud Schepereel, Dragan Subotic, Paul Van Schil, Thomy Tonia, Clare Williams, Thierry Berghmans
Summary: This guideline provides good quality recommendations in lung cancer care, based on systematic reviews and evidence syntheses. The recommendations cover various quality improvement measures, such as avoiding delays in diagnosis and treatment, integrating multidisciplinary teams, adhering to guidelines, and using specific tools for decision-making. The recommendations should be periodically updated as new evidence becomes available.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Oncology
Alan McWilliam, Azadeh Abravan, Kathryn Banfil, Corinne Faivre-Finn, Marcel van Herk
Summary: The dose to the base of the heart is associated with overall survival, explaining the worse survival in the high-dose arm of lung cancer treatment. By avoiding the heart subregion dose, future dose escalation trials may be feasible.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Marina C. Garassino, Corinne Faivre-Finn
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Engineering, Biomedical
Robert W. Chuter, Frank Brewster, Louise Retout, Anthea Cree, Nesrin Akturk, Rosie Hales, Rebecca Benson, Peter Hoskin, Alan McWilliam
Summary: This study investigated the use of a dual isocentre technique and adaptive workflows to expand the range of cervical cancer patients who can benefit from MR-Linac treatment. The results showed that dual isocentre adapted plans provided better coverage of the treatment area, with a larger benefit for patients without lymph node involvement.
PHYSICS IN MEDICINE AND BIOLOGY
(2023)
Article
Oncology
Saskia A. Cooke, Dirk de Ruysscher, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Corinne Faivre-Finn, Edith M. T. Dieleman, Rolf Lewensohn, Judi N. A. van Diessen, Karolina Sikorska, Ferry Lalezari, Wouter Vogel, Wouter van Elmpt, Eugene M. F. Damen, Jan -Jakob Sonke, Jose S. A. Belderbos
Summary: This study aimed to evaluate the ability of radiation dose escalation to improve local control in patients with locally advanced non-small-cell lung cancer. The results showed that both whole primary tumour dose escalation and PET-defined subvolume dose escalation can improve local control. However, both strategies also led to unexpected high rates of toxicity. Therefore, it is recommended to improve dose escalation strategies by considering dose differentiation, better patient selection, and improved protection of central structures.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Nicholas S. Moore, Alan McWilliam, Sanjay Aneja
Summary: Machine learning (ML) and artificial intelligence (AI) have shown potential in improving the care of bladder cancer patients. This review focuses on recent advances in ML and AI applicable to bladder cancer care and discusses potential next steps for clinical implementation. Algorithms have been used to generate predictive models for prognosis and clinical outcomes using clinical records, pathology, and radiology data. AI has also been used for auto-contouring and efficient creation of workflows involving multiple treatment plans. The review also highlights emerging methods to improve the interpretability and reliability of algorithms.
SEMINARS IN RADIATION ONCOLOGY
(2023)
Article
Oncology
Eliana Vasquez Osorio, Azadeh Abravan, Andrew Green, Marcel van Herk, Lip Wai Lee, Deborah Ganderton, Andrew Mcpartlin
Summary: This study explores the relationship between radiation therapy dose to normal head and neck structures and dysphagia after treatment. The results suggest that the mean dose to the inferior section of the brain stem is strongly associated with dysphagia 1 year posttreatment, possibly due to its involvement with the swallowing centers in the medulla oblongata.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Romaana Mir, Nicki Groom, Hitesh B. Mistry, Elena Wilson, Corinne Faivre-Finn
Summary: This study conducted comprehensive contouring, dosimetry, and treatment delivery quality assurance in radiotherapy, and examined the impact of protocol variations on patient outcomes. Non-compliant heart contours were associated with increased dose delivered to the heart organ at risk (OAR), but unacceptable variations did not affect toxicity or survival outcomes.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Alyaa M. Ajabnoor, Rosa Parisi, Salwa S. Zghebi, Darren M. Ashcroft, Corinne Faivre-Finn, Charlotte Morris, Mamas A. Mamas, Evangelos Kontopantelis
Summary: The study examines the association between certain types of cancer and the balance between stroke and bleeding risk in patients with atrial fibrillation.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jim Zhong, Russell Frood, Alan McWilliam, Angela Davey, Jane Shortall, Martin Swinton, Oliver Hulson, Catharine M. West, David Buckley, Sarah Brown, Ananya Choudhury, Peter Hoskin, Ann Henry, Andrew Scarsbrook
Summary: This study aimed to develop a machine learning model based on radiomic features extracted from whole prostate gland MRI for prediction of tumor hypoxia pre-radiotherapy. The results showed that radiomic features can be used to assist in individualized treatment optimization.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)